Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Drägerwerk AG & Co. KGaA specializes in medical and safety technology, focusing on critical care, anesthesia, and emergency medical services. The company operates globally, with significant market presence in Europe and North America, and is recognized for its innovative products such as ventilators and monitoring systems, which are critical in hospital settings.
Drägerwerk generates revenue primarily through the sale of medical devices and safety technology products. The company benefits from strong pricing power due to its established brand reputation and innovative product offerings. Its competitive advantages include a robust R&D pipeline and a comprehensive service network that enhances customer loyalty.
Changes in hospital spending on medical devices, particularly in Europe and North America
Regulatory approvals for new medical technologies
Trends in critical care demand, especially during health crises
Currency fluctuations impacting international sales
Technological disruption from emerging medical technologies
Regulatory changes impacting product approvals and market access
Intensifying competition from other medical device manufacturers
Potential for price erosion in key product segments
Low liquidity risk due to a current ratio of 2.07
Potential pension obligations impacting cash flow
moderate - The healthcare sector is generally resilient, but Drägerwerk's performance can be influenced by overall economic conditions affecting hospital budgets and capital expenditures.
Interest rates can affect Drägerwerk's financing costs for R&D and capital expenditures. Higher rates may also impact hospital borrowing costs, potentially reducing spending on new equipment.
minimal - The company has a low debt-to-equity ratio of 0.14, indicating limited reliance on external financing.
value - The company's low price-to-sales ratio of 0.4x suggests it may be undervalued relative to its peers, appealing to value investors.
moderate - Historical volatility is consistent with the healthcare sector, though specific beta data is not available.
